Microencapsulation: Which Companies Are Building the Next Generation of Drug Delivery?

Microencapsulation is becoming an important formulation technology for pharmaceutical manufacturers, biotechnology companies and nutraceutical developers. It involves enclosing active ingredients within microscopic particles or protective carrier materials to improve stability, manage drug release and support specific delivery requirements.

For pharmaceutical companies, the technology can help address challenges involving poorly soluble drugs, sensitive biological ingredients, unpleasant tastes and the need for sustained or delayed release.

The commercial opportunity extends beyond the encapsulation process itself. It includes specialised polymers, biodegradable carrier materials, formulation development, particle engineering and large-scale manufacturing.

Download Customized Sample Before Investing: https://www.towardshealthcare.com/download-sample/6386 

How Microencapsulation Works

Microencapsulation surrounds an active ingredient with a protective coating or matrix. Depending on the formulation, the resulting particles can release their contents through diffusion, dissolution, degradation or changes in environmental conditions.

Common techniques include:

• Spray drying: Converts liquid formulations into dry particles using controlled heat and airflow.

• Coacervation: Uses polymer phase separation to form a coating around active ingredients.

• Fluid-bed coating: Applies functional coatings to particles, pellets or granules.

• Emulsion-based methods: Disperse active ingredients within droplets before forming encapsulated particles.

• Interfacial polymerisation: Forms a polymer shell around droplets or dispersed materials.

The choice of process depends on the active ingredient, carrier material, particle size, release profile and intended dosage form.

Pharmaceutical Applications Are Expanding

Microencapsulation can support several formulation objectives, although the benefits depend on the drug, materials and manufacturing process.

These technologies are particularly relevant to oral solid dosage forms, multiparticulate formulations, selected injectable systems and emerging biologic delivery approaches.

However, microencapsulation does not automatically improve bioavailability or achieve tissue-specific targeting. Those outcomes require evidence from formulation testing, pharmacokinetic studies and clinical development.

Key Segments Creating Commercial Opportunities

1. Pharmaceutical drug delivery

Drug manufacturers use encapsulation and functional coating technologies to develop sustained-release formulations, taste-masked medicines and products with improved protection against environmental or gastrointestinal conditions.

Companies developing complex generics and reformulated medicines may also use these technologies to differentiate products and address formulation limitations.

2. Nutraceuticals and dietary supplements

Vitamins, minerals, probiotics, omega-3 oils and plant-derived bioactive ingredients can be sensitive to heat, oxygen, moisture and light.

Encapsulation can help protect these ingredients during processing and storage. It can also support controlled release and mask unpleasant flavours in powders, capsules and functional foods.

3. Biotechnology and biologics

Enzymes, peptides, proteins and microorganisms can require specialised delivery systems because their activity may be affected by temperature, pH and other environmental conditions.

Research into polymeric particles, lipid-based carriers and biodegradable materials is creating opportunities for more specialised formulation approaches.

4. Cosmetics and personal care

Microencapsulation can protect fragrances, vitamins, antioxidants and other cosmetic actives. Controlled release can support longer-lasting product performance and reduce premature exposure to environmental conditions.

Which Companies Are Building the Technology?

The competitive landscape includes pharmaceutical polymer suppliers, excipient manufacturers and specialised delivery technology developers. The companies below operate in relevant areas of formulation and controlled delivery, although their technologies are not all identical microencapsulation platforms.

These companies illustrate different parts of the formulation ecosystem: polymer development, API solubilisation, functional coatings and controlled-release systems.

For example, Evonik's EUDRAGIT® portfolio includes polymers for multiparticulate dosage forms and functional coatings. BASF's Kollicoat® range addresses sustained release, moisture protection and taste masking.

Lubrizol's Apisolex™ focuses on solubility enhancement for difficult-to-formulate APIs. The company reported in June 2025 that a formulation using the excipient had entered Phase I clinical trials.

Colorcon's controlled-release portfolio includes technologies for modifying drug release from tablets and multiparticulate formulations.

Where Does the Industry Face Technical Challenges?

Despite its potential, commercial adoption depends on solving several formulation and manufacturing problems.

Encapsulation efficiency: Manufacturers must ensure that the intended quantity of active ingredient remains inside the carrier material. Drug loss during processing can affect product performance and production economics.

Particle-size consistency: Particle size and distribution can influence dissolution, release rates, stability and product uniformity. Maintaining consistency across production batches is essential.

Scale-up complexity: A process that works in laboratory conditions may behave differently in commercial manufacturing. Changes in mixing, temperature, drying and coating conditions can affect the final product.

Material compatibility: Polymers and carrier materials must remain compatible with the active ingredient throughout manufacturing, storage and administration.

Regulatory and quality requirements: Pharmaceutical manufacturers must establish appropriate controls for excipient quality, residual solvents, impurities, stability, release performance and batch reproducibility.

Business Opportunities for Manufacturers and Investors

The next phase of development may create opportunities across several specialised areas.

• Biodegradable encapsulation materials: Developing polymer systems that break down safely and predictably can support specialised pharmaceutical and biotechnology applications.

• Peptide and biologic delivery: Formulation platforms that protect sensitive molecules from degradation could address important delivery challenges.

• Poorly soluble API formulations: Solubilisation and encapsulation technologies can support new formulations, complex generics and product lifecycle management.

• Contract microencapsulation services: Pharmaceutical companies may outsource particle engineering, formulation development, pilot production and specialised encapsulation.

• Continuous and scalable manufacturing: Equipment and process technologies that improve production consistency could reduce development and manufacturing barriers.

• Nutraceutical ingredient protection: Suppliers can develop encapsulated probiotics, vitamins and bioactive ingredients for supplement manufacturers.

For investors, the key evaluation factors include intellectual property, material performance, manufacturing scalability, regulatory experience, customer partnerships and the number of formulation programmes using the technology.

What Should Pharmaceutical Leaders Track?

The commercial potential of microencapsulation will depend on more than the number of new materials entering development. Decision-makers should assess:

1. Which companies own proprietary encapsulation materials or manufacturing processes?

2. Which technologies have progressed from laboratory research to commercial production?

3. Which platforms support peptides, biologics and poorly soluble APIs?

4. How do competing materials perform in encapsulation efficiency, release control and stability?

5. Which pharmaceutical manufacturers, CDMOs and biotechnology companies are adopting these systems?

Understanding these factors can help identify technology partners, licensing opportunities and investment targets before a formulation platform becomes widely adopted.

How Towards Healthcare Supports Industry Decision-Making

Towards Healthcare helps pharmaceutical, biotechnology and materials-sector decision-makers assess company capabilities, technology developments and competitive opportunities.

Its strategic intelligence approach can support:

• Complete Master Datasets: Company profiles, product portfolios, technology capabilities and development activities.

• Competitive Quadrants: Comparison of companies by technology focus, product capabilities and competitive positioning.

• Customized Dashboards: Structured intelligence for tracking companies, technologies and emerging opportunities.

• Buyer Identification: Identification of potential pharmaceutical manufacturers, CDMOs and other commercial partners.

• GTM Strategy: Assessment of regional opportunities, target customers and potential partnership routes.

Microencapsulation is not simply a protective coating technology. It is an enabling formulation platform that could influence how complex medicines and sensitive ingredients are manufactured, stored and delivered.

Companies that combine material innovation with reliable scale-up and proven formulation performance may be positioned to capture important opportunities across pharmaceutical and biotechnology development.

Explore microencapsulation company intelligence, technology benchmarking and pharmaceutical opportunities with Towards Healthcare.

About Us

Healthcare WebWire is a part of Towards Healthcare, which is a healthcare intelligence and market research company specializing in market intelligence, competitive intelligence, customer intelligence, pipeline intelligence, market sizing and commercial strategy across pharmaceutical, biotechnology, medical device and healthcare markets.

Contact us for quick meeting, customized data, free samples or further enquiry at [email protected]

Europe Region - +44 778 256 0738

North America Region - +1 8044 4193 44

APAC Region: +91 9356 9282 04

Visit Our Website: https://www.towardshealthcare.com

                      Find us on social platforms: LinkedIn | Twitter | Instagram